Retrospective Study
Copyright ©The Author(s) 2018.
World J Clin Oncol. Sep 14, 2018; 9(5): 110-118
Published online Sep 14, 2018. doi: 10.5306/wjco.v9.i5.110
Table 3 Contingency table of tumor response with FOLFIRI3-aflibercept according to prior tumor response with irinotecan [n = 35, n (%)]
FOLFIRI3-aflibercept
CR/PRSDPDNEAll
Prior irinotecan-based regimenCR/PR537015 (42.8)
SD442010 (28.6)
PD12317 (20.0)
NE20103 (8.6)
All12 (34.3)9 (25.7)13 (37.1)1 (2.8)35